Related Experiment Video
Updated: Jul 5, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate
Shuang Cai1, Yumei Xie, Taryn R Bagby
1Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas, USA.
The Journal of Surgical Research
|May 24, 2008
Summary
Targeting breast cancer lymph node metastasis with cisplatin-hyaluronan conjugates increases localized drug dose and reduces systemic toxicity. This novel lymphatic drug delivery method shows promise for treating at-risk regional lymph nodes in early-stage breast cancer.
Area of Science:
- Oncology
- Drug Delivery
- Nanotechnology
Background:
- Breast cancer commonly metastasizes to regional lymph nodes, making axillary lymph node evaluation critical in early-stage disease.
- Systemic chemotherapy agents often cause significant side effects, impacting treatment tolerance and efficacy.
- Developing targeted therapies is essential to improve localized treatment and minimize systemic toxicity.
Purpose of the Study:
- To investigate the efficacy of lymphatically targeted cisplatin carriers for treating lymphatic metastases.
- To determine if this targeted approach can increase localized drug dosage in lymph nodes.
- To assess the potential for reducing systemic toxicities associated with chemotherapy.
Main Methods:
- Hyaluronan (HA), a biocompatible polymer that follows lymphatic drainage, was used to form non-covalent complexes with cisplatin.
- Cisplatin-HA complexes were administered via subcutaneous injection into the mammary fat pad of female rats.
- Tissue distribution and drug concentration in lymphatic tissues were analyzed.
Main Results:
- Cisplatin-HA conjugates demonstrated high in vitro anti-tumor activity, comparable to free cisplatin.
- The conjugates were well-tolerated in rodents, showing no significant injection site morbidity or major organ toxicity.
- Administration of cisplatin-HA resulted in a 74% increase in the area-under-the-curve of cisplatin in axillary lymph nodes compared to free cisplatin.
Conclusions:
- This study presents a novel intralymphatic drug delivery strategy for breast cancer, targeting regional lymph nodes.
- The approach shows potential for preferential treatment of at-risk lymph nodes while avoiding systemic toxicities.
- Further in vivo studies are warranted to evaluate survival, toxicity, and pharmacokinetics for potential human trials.
